<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581710</url>
  </required_header>
  <id_info>
    <org_study_id>CHA-121</org_study_id>
    <nct_id>NCT01581710</nct_id>
  </id_info>
  <brief_title>Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children.</brief_title>
  <official_title>A Double-blind, Randomized, Cross-over Design Study to Compare the Lung Function Measure of Montelukast Versus Placebo in Children With Mild Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHA University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CHA University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to identify markers to prove rapid improvement of lung function, airway
      inflammation and bronchodilator response after 2-week LTRA administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blind, placebo-controlled, cross-over study with a washout
      period of at least one week between each study period.

      After an initial screening visit, subjects entered a screening period of one to two weeks to
      ensure clinical stability without medication, which means absence of daily asthma symptoms.
      Eligible subjects were randomized into either the treatment portion of the trial, in which
      subjects received montelukast (4 mg or 5 mg) or matching placebo monotherapy in a randomized
      manner. During each treatment period, which lasted 2 weeks, the study medication was
      administered between 8:00 and 9:00 A.M. Short acting bronchodilator (for severe symptoms) was
      permitted during the study period but was withheld 24 hours prior to bronchodilator challenge
      test.

      Inclusion criteria will be mild persistent asthma children old enough to cooperate on
      performing pulmonary function testing, children with no respiratory symptoms 4 weeks prior to
      the beginning of the study. Exclusion criteria will be the following: respiratory symptoms
      including cough, wheezing, dyspnea, or shortness of breath, presence of acute or chronic
      upper respiratory infections, anatomical nasal disorders (ex, nasal polyps, septum deviation,
      etc.), previous or current specific immunotherapy, use of systemic corticosteroids, or
      admission or visit of the emergency department during the previous 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Lung Function of Rrs 5 With IOS Before the Bronchodilator (Pre-Rrs5)</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Pre Rrs 5: Resistance at 5Hz before the administration of bronchodilator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Lung Function of Xrs5 With IOS Before the Bronchodilator (Pre-Xrs 5)</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Pre Xrs 5: Reactance at 5Hz before the administration of bronchodilator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Lung Function of Rrs10 With IOS Before the Bronchodilator</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Pre Rrs10: Resistance at 10Hz before the administration of bronchodilator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Lung Function of Xrs10 With IOS Before the Bronchodilator (Pre-Xrs10)</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Pre Xrs 10: Reactance at 10Hz before the administration of bronchodilator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Lung Function of FEV1 Before the Bronchodilator</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>baseline lung function in forced expiratory volume in 1 second before the administration of bronchodilator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Lung Function of FEV1/FVC Before the Bronchodilator</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>baseline lung function in forced expiratory volume in 1 second/forced vital capacity before the administration of bronchodilator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Lung Function in MMEF</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Baseline lung function in maximal mid-expiratory flow before the administration of bronchodilator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative Change (%) of FEV1 After the Bronchodilator</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>Relative change in percentage of FEV1 after the bronchodilator, 2weeks after placebo and montelukast administration Relative change (%) in FEV1 = (((FEV1 post-bronchodilator)-(FEV1 pre-bronchodilator))/baseline FEV1) x 100</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Mild Persistent Asthma</condition>
  <arm_group>
    <arm_group_label>montelukast to placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Washout</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to montelukast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast to placebo</intervention_name>
    <description>Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks</description>
    <arm_group_label>montelukast to placebo</arm_group_label>
    <other_name>SINGULAIR 4mg or 5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to montelukast</intervention_name>
    <description>Subjects will receive matching placebo. Each treatment period consists of 2 weeks</description>
    <arm_group_label>Placebo to montelukast</arm_group_label>
    <other_name>SINGULAIR 4mg or 5mg matching placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children diagnosed with mild persistent asthma patients based on the GINA guidelines

          -  children old enough to cooperate in performing pulmonary function testing

          -  legal guardians who sufficiently listen to the purpose and voluntarily agree with the
             participation to sign a written consent approved by IRB

          -  children with no respiratory symptoms 4 weeks prior to the beginning of the study

          -  children without chronic respiratory symptoms.

        Exclusion Criteria:

          -  presence of acute or chronic upper respiratory infections, anatomical nasal disorders
             (ex, nasal polyps, septum deviation, etc.), previous or current specific
             immunotherapy.

          -  use of systemic corticosteroids in past 4 weeks.

          -  admission or visit of the emergency department in past 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Man Yong Han</last_name>
    <role>Principal Investigator</role>
    <affiliation>specify Unaffiliated</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <results_first_submitted>July 31, 2017</results_first_submitted>
  <results_first_submitted_qc>March 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2018</results_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHA University</investigator_affiliation>
    <investigator_full_name>Man Yong Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Leukotriene Antagonists</keyword>
  <keyword>Bronchodilator response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Montelukast to Placebo</title>
          <description>Montelukast to placebo: Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo to Montelukast</title>
          <description>Placebo to montelukast: Subjects will receive matching placebo. Each treatment period consists of 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (14days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (14days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (14days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Measure Analysis Population Description: two participants did not complete the second set test due to symptom aggravation</population>
      <group_list>
        <group group_id="B1">
          <title>Subjects</title>
          <description>All subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.41" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lung function (Forced Expiratory Volume 1, predicted %)</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.9" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lung function (Forced Expiratory Volume 1/Forced Vital Capacity, predicted %)</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.1" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>oscillometric lung function (Resistance at 5Hz, z-score)</title>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.36" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>oscillometric lung fuction(Reactance at 5Hz, z-score)</title>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-1.14" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Lung Function of Rrs 5 With IOS Before the Bronchodilator (Pre-Rrs5)</title>
        <description>Pre Rrs 5: Resistance at 5Hz before the administration of bronchodilator</description>
        <time_frame>up to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Lung Function</title>
            <description>Before placebo or montelukast administration</description>
          </group>
          <group group_id="O2">
            <title>2 Weeks After Placebo Administration</title>
            <description>Subjects will receive placebo. Each treatment period consists of 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>2 Weeks After Montelukast Administration</title>
            <description>Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Lung Function of Rrs 5 With IOS Before the Bronchodilator (Pre-Rrs5)</title>
          <description>Pre Rrs 5: Resistance at 5Hz before the administration of bronchodilator</description>
          <units>kPa/L/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.15"/>
                    <measurement group_id="O2" value="0.74" spread="0.20"/>
                    <measurement group_id="O3" value="0.73" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Lung Function of Xrs5 With IOS Before the Bronchodilator (Pre-Xrs 5)</title>
        <description>Pre Xrs 5: Reactance at 5Hz before the administration of bronchodilator</description>
        <time_frame>up to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Lung Function</title>
            <description>Before placebo or montelukast administration</description>
          </group>
          <group group_id="O2">
            <title>2 Weeks After Placebo Administration</title>
            <description>Subjects will receive placebo. Each treatment period consists of 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>2 Weeks After Montelukast Administration</title>
            <description>Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Lung Function of Xrs5 With IOS Before the Bronchodilator (Pre-Xrs 5)</title>
          <description>Pre Xrs 5: Reactance at 5Hz before the administration of bronchodilator</description>
          <units>kPa/L/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.11"/>
                    <measurement group_id="O2" value="-0.36" spread="0.15"/>
                    <measurement group_id="O3" value="-0.34" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Lung Function of Rrs10 With IOS Before the Bronchodilator</title>
        <description>Pre Rrs10: Resistance at 10Hz before the administration of bronchodilator</description>
        <time_frame>up to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Lung Function</title>
            <description>Before placebo or montelukast administration</description>
          </group>
          <group group_id="O2">
            <title>2 Weeks After Placebo Administration</title>
            <description>Subjects will receive placebo. Each treatment period consists of 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>2 Weeks After Montelukast Administration</title>
            <description>Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Lung Function of Rrs10 With IOS Before the Bronchodilator</title>
          <description>Pre Rrs10: Resistance at 10Hz before the administration of bronchodilator</description>
          <units>kPa/L/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.11"/>
                    <measurement group_id="O2" value="0.55" spread="0.15"/>
                    <measurement group_id="O3" value="0.55" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Lung Function of Xrs10 With IOS Before the Bronchodilator (Pre-Xrs10)</title>
        <description>Pre Xrs 10: Reactance at 10Hz before the administration of bronchodilator</description>
        <time_frame>up to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Lung Function</title>
            <description>Before placebo or montelukast administration</description>
          </group>
          <group group_id="O2">
            <title>2 Weeks After Placebo Administration</title>
            <description>Subjects will receive placebo. Each treatment period consists of 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>2 Weeks After Montelukast Administration</title>
            <description>Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Lung Function of Xrs10 With IOS Before the Bronchodilator (Pre-Xrs10)</title>
          <description>Pre Xrs 10: Reactance at 10Hz before the administration of bronchodilator</description>
          <units>kPa/L/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.22"/>
                    <measurement group_id="O2" value="-0.20" spread="0.10"/>
                    <measurement group_id="O3" value="-0.19" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Lung Function of FEV1 Before the Bronchodilator</title>
        <description>baseline lung function in forced expiratory volume in 1 second before the administration of bronchodilator</description>
        <time_frame>up to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Lung Function</title>
            <description>Before placebo or montelukast administration</description>
          </group>
          <group group_id="O2">
            <title>2 Weeks After Placebo Administration</title>
            <description>Subjects will receive placebo. Each treatment period consists of 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>2 Weeks After Montelukast Administration</title>
            <description>Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Lung Function of FEV1 Before the Bronchodilator</title>
          <description>baseline lung function in forced expiratory volume in 1 second before the administration of bronchodilator</description>
          <units>L/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0.41"/>
                    <measurement group_id="O2" value="1.25" spread="0.47"/>
                    <measurement group_id="O3" value="1.28" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Lung Function of FEV1/FVC Before the Bronchodilator</title>
        <description>baseline lung function in forced expiratory volume in 1 second/forced vital capacity before the administration of bronchodilator</description>
        <time_frame>up to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Lung Function</title>
            <description>Before placebo or montelukast administration</description>
          </group>
          <group group_id="O2">
            <title>2 Weeks After Placebo Administration</title>
            <description>Subjects will receive placebo. Each treatment period consists of 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>2 Weeks After Montelukast Administration</title>
            <description>Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Lung Function of FEV1/FVC Before the Bronchodilator</title>
          <description>baseline lung function in forced expiratory volume in 1 second/forced vital capacity before the administration of bronchodilator</description>
          <units>none (ratio)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.55" spread="16.33"/>
                    <measurement group_id="O2" value="83.04" spread="1.22"/>
                    <measurement group_id="O3" value="85.93" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Baseline Lung Function in MMEF</title>
        <description>Baseline lung function in maximal mid-expiratory flow before the administration of bronchodilator</description>
        <time_frame>up to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Baseline Lung Function</title>
            <description>Before placebo or montelukast administration</description>
          </group>
          <group group_id="O2">
            <title>2 Weeks After Placebo Administration</title>
            <description>Subjects will receive placebo. Each treatment period consists of 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>2 Weeks After Montelukast Administration</title>
            <description>Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Lung Function in MMEF</title>
          <description>Baseline lung function in maximal mid-expiratory flow before the administration of bronchodilator</description>
          <units>L/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.54"/>
                    <measurement group_id="O2" value="1.38" spread="0.59"/>
                    <measurement group_id="O3" value="1.46" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change (%) of FEV1 After the Bronchodilator</title>
        <description>Relative change in percentage of FEV1 after the bronchodilator, 2weeks after placebo and montelukast administration Relative change (%) in FEV1 = (((FEV1 post-bronchodilator)-(FEV1 pre-bronchodilator))/baseline FEV1) x 100</description>
        <time_frame>up to 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2 Weeks After Placebo Administration</title>
            <description>Subjects will receive placebo. Each treatment period consists of 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>2 Weeks After Montelukast Administration</title>
            <description>Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change (%) of FEV1 After the Bronchodilator</title>
          <description>Relative change in percentage of FEV1 after the bronchodilator, 2weeks after placebo and montelukast administration Relative change (%) in FEV1 = (((FEV1 post-bronchodilator)-(FEV1 pre-bronchodilator))/baseline FEV1) x 100</description>
          <units>% (relative change)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.68" spread="13.31"/>
                    <measurement group_id="O2" value="5.65" spread="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Baseline Lung Function</title>
          <description>Before placebo or montelukast administration</description>
        </group>
        <group group_id="E2">
          <title>2 Weeks After Placebo Administration</title>
          <description>Subjects will receive placebo. Each treatment period consists of 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>2 Weeks After Montelukast Administration</title>
          <description>Subjects will receive montelukast (4mg or 5mg) Each treatment period consists of 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. HAN, MAN YONG</name_or_title>
      <organization>CHA UNIVERSITY</organization>
      <phone>82-31-780-6262</phone>
      <email>drmesh@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

